Subtype
Biliary Tract Carcinoma
CI-CAN-00001970Explore in graph →
238 active trials3 approved drugs29 evidence items
- NCIt
- C156781
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001970Explore in graph →
Clinical trials
823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (111)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06098547 | LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)(LIRICA) | recruiting | N/A | 10 | Azienda Sanitaria OspedalieraOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT00320918 | Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib | terminated | — | 10 | University of New MexicoOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06194695 | DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma(CCGLC-009) | unknown | — | 100 | Ze-yang Ding, MDOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02611453 | Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP | unknown | N/A | 40 | University of VirginiaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma(FIDES-01) | completed | Phase 2 | 148 | Basilea PharmaceuticaINDUSTRY | 11 | Dec 19, 2023 | clinicaltrials |
| NCT05845554 | Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma | unknown | — | 300 | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05600803 | Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions | unknown | — | 236 | Soonchunhyang University HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04596865 | Recurrence After Whipple's (RAW) Study | completed | — | 1,484 | University Hospital Plymouth NHS TrustOTHER | 8 | Nov 18, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT02232633 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | completed | Phase 2 | 45 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06106750 | Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent | unknown | N/A | 122 | First People's Hospital of HangzhouOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03833661 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | completed | Phase 2 | 159 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 9 | Oct 25, 2023 | clinicaltrials |
| NCT06081322 | A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors(CISPD-5) | unknown | Phase 1 | 29 | Zhejiang UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06048289 | Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy | unknown | — | 150 | Zhejiang Cancer HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06047990 | Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction(BICRYOB) | unknown | N/A | 20 | Brno University HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer(RELEASE) | terminated | Phase 2 | 41 | PCI Biotech ASINDUSTRY | 14 | Sep 11, 2023 | clinicaltrials |
| NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | completed | Phase 1 | 24 | HutchmedINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03637569 | The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer | recruiting | — | 1,000 | Samsung Medical CenterOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05681949 | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards(ADBoard) | unknown | N/A | 1,200 | Charite University, Berlin, GermanyOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03003065 | Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers(PDT) | completed | Phase 2 | 10 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | unknown | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05233293 | Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma | unknown | N/A | 200 | First People's Hospital of HangzhouOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2023 | clinicaltrials |
| NCT04072445 | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05957250 | [68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer(PANSCAN-1) | unknown | N/A | 63 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05595122 | EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction(SCORPION-II-p) | unknown | N/A | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04445532 | Hepatobiliary Tumors Tissue Samples Acquisition | unknown | — | 450 | Peking Union Medical College HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | terminated | Phase 2 | 143 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03278106 | TAS-102 in Treating Advanced Biliary Tract Cancers | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | terminated | — | 59 | Washington University School of MedicineOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03473574 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients(IMMUCHEC) | completed | Phase 2 | 128 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2024source: clinicaltrials